(Q46230407)

20 December 2017

title

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours (English)

1 reference

20 December 2017

0 references

1 reference

1 reference

8

1 reference

20 December 2017

author name string

Hans Skovgaard Poulsen

1

1 reference

20 December 2017

Kirsten Grunnet

2

1 reference

20 December 2017

Morten Sorensen

3

1 reference

20 December 2017

Preben Olsen

4

1 reference

20 December 2017

Benedikte Hasselbalch

5

1 reference

20 December 2017

Knud Nelausen

6

1 reference

20 December 2017

Michael Kosteljanetz

7

1 reference

20 December 2017

language of work or name

1 reference

1 January 2009

1 reference

20 December 2017

published in

Acta Oncologica

1 reference

20 December 2017

volume

48

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

52-58

1 reference

20 December 2017

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Recent developments in the use of chemotherapy in brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Brain tumor imaging in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Thalidomide as an anti-angiogenic agent in relapsed gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Molecularly targeted therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Chemotherapy induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

Significance of hemorrhage into brain tumors: clinicopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802537924

10.1080/02841860802537924

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19031176

1 reference

20 December 2017